Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00540 ...
Drug Name Nortriptyline
Molecular Weight 263.3767
Molecular Formula C19H21N
CAS Number 72-69-5
SMILES CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
External Links
DRUGBANK DB00540
T3DB T3D2818
PubChem Compound 4543
PDR 1575
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 3.9 - 3.9 - Lead Optimization for Medicinal Chemists (2012)
Boiling Point 396.62 ℃ 396.62 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB1317147.aspx
Melting Point 58.0 ℃ 58 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB1317147.aspx
Water Solubility 0.87 mg/L 0.00087 g/L http://www.hmdb.ca/metabolites/HMDB0014680
pKa 9.7 - 9.7 - https://www.chemicalbook.com/ChemicalProductProperty_US_CB1317147.aspx
Log S -5.5 - -5.5 - http://www.hmdb.ca/metabolites/HMDB0014680

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 65.0 % 45-85 % PO, oral; DRUGBANK
Bioavailability 51.0 % 51±5 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 36345984.6 ng/ml 138(40-350) mM PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 7.8 h 7-8.5 h PO, oral; DRUGBANK
T Max 8.5 h 7-10 h PO, oral; The Pharmacological Basis of Therapeutics
Clearance 54.0 L/h 54.0 L/h Plasma clearance; normal,healthy; DRUGBANK
Clearance 30.6 L/h 30.6±6.9 L/h Average clearance; DRUGBANK
Clearance 0.43 L/h/kg 7.2±1.8 ml/min/kg hydrolysis; RD, renal impairment, Renal disease，including uremia → ;inflammation ↓ ;Somking → ; The Pharmacological Basis of Therapeutics
Clearance 0.60 L/h/kg 10 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1633.0 L 1633±268 L Apparent volume of distribution; intravenous injection, IV; DRUGBANK
Volume of Distribution 18.0 L/kg 18±4 L/kg Apparent volume of distribution; The Pharmacological Basis of Therapeutics
Volume of Distribution 22.0 L/kg 22 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 26.0 h ~26(16-38) h elimination half-life; normal,healthy; DRUGBANK
Half-life 39.0 h ~39 h different study; DRUGBANK
Half-life 31.0 h 31±13 h RD, renal impairment, Renal disease，including uremia → ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 30.0 h 30 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 405.0 mg/kg 405.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Eliminate Route 33.0 % ~33 % Urinary excretion; Oral single dose; DRUGBANK
Eliminate Route 2.0 % 2 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 2.0 % 2±1 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 93.0 % ~93 % plasma proteins; DRUGBANK
Protein Binding 92.0 % 92±2 % HL,hyperlipoproteinemia ↑ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adolescents 50.0 mg/day 50 mg/day PO, oral Nortriptyline Hydrochloride Oral Solution nortriptyline hydrochloride PDR
Max dose for adults 150.0 mg/day 150 mg/day PO, oral Nortriptyline Hydrochloride Oral Solution nortriptyline hydrochloride PDR
Max dose for geriatric 50.0 mg/day 50 mg/day PO, oral Nortriptyline Hydrochloride Oral Solution nortriptyline hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1